

# Alicia Gutiérrez-Valencia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8830075/publications.pdf>

Version: 2024-02-01

38  
papers

600  
citations

840776

11  
h-index

642732

23  
g-index

42  
all docs

42  
docs citations

42  
times ranked

927  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2007, 45, 969-974.	5.8	178
2	Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2128-2139.	10.5	81
3	Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 624-632.	4.0	44
4	Stepped-Dose Versus Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events. <i>Annals of Internal Medicine</i> , 2009, 151, 149.	3.9	40
5	Lopinavir Plasma Concentrations and Virological Outcome with Lopinavir-Ritonavir Monotherapy in HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3746-3751.	3.2	20
6	Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy. <i>Aids</i> , 2014, 28, 201-208.	2.2	15
7	<i>Enterococcus faecalis</i> Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives. <i>Antibiotics</i> , 2020, 9, 657.	3.7	15
8	Darunavir Cmin and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients. <i>Antiviral Therapy</i> , 2014, 19, 443-447.	1.0	14
9	Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy. <i>Medicine (United States)</i> , 2015, 94, e781.	1.0	14
10	Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2017, 65, 551-556.	5.8	14
11	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1 $\beta$ , Early Predictors of Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 2259.	3.6	14
12	Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. <i>PLoS ONE</i> , 2018, 13, e0205777.	2.5	13
13	Efficacy and Safety of Pegylated Interferon plus Ribavirin in HIV and Hepatitis C Virus Coinfected Patients with Advanced Immunosuppression. <i>Clinical Infectious Diseases</i> , 2009, 49, e84-e91.	5.8	12
14	Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 681-684.	3.0	11
15	Fetuin A, inter-alpha-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. <i>Clinical and Translational Medicine</i> , 2022, 12, e704.	4.0	11
16	Ampicillin Plus Ceftriaxone Combined Therapy for <i>Enterococcus faecalis</i> Infective Endocarditis in OPAT. <i>Journal of Clinical Medicine</i> , 2022, 11, 7.	2.4	11
17	Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir. <i>Clinical Infectious Diseases</i> , 2014, 58, 268-273.	5.8	8
18	Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e1-e5.	2.1	8

#	ARTICLE	IF	CITATIONS
19	Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	8
20	Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial. <i>Stem Cells Translational Medicine</i> , 2021, 10, 534-541.	3.3	8
21	Deciphering the quality of SARS-CoV-2 specific T cell response associated with disease severity, immune memory and heterologous response. <i>Clinical and Translational Medicine</i> , 2022, 12, e802.	4.0	8
22	The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. <i>Aids</i> , 2013, 27, 1941-1947.	2.2	6
23	Higher Activation in CD4 <sup>+</sup> T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 6-11.	1.1	6
24	Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. <i>Vaccine</i> , 2019, 37, 2758-2763.	3.8	6
25	Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1151.e9-1151.e16.	6.0	6
26	Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations. <i>Journal of the International AIDS Society</i> , 2018, 21, e25072.	3.0	5
27	Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw487.	3.0	4
28	Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naïve HIV-infected patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 200-207.	3.0	4
29	Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3257-3262.	3.2	3
30	No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients. <i>PLoS ONE</i> , 2018, 13, e0203452.	2.5	3
31	Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
32	Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. <i>PLoS ONE</i> , 2012, 7, e48959.	2.5	2
33	PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors. <i>ACS Applied Bio Materials</i> , 2021, 4, 4789-4799.	4.6	2
34	HIV-1 p24 and CD4 + T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 174-178.	0.5	1
35	Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy. <i>Annals of Hematology</i> , 2019, 98, 1953-1959.	1.8	1
36	Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?. <i>Medicine (United States)</i> , 2015, 94, e1743.	1.0	0

#	ARTICLE	IF	CITATIONS
37	Early initiation of antiretroviral therapy: debate over?. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 769.	9.1	0
38	Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. <i>PLoS ONE</i> , 2022, 17, e0269875.	2.5	0